Literature DB >> 21671164

Perioperative care of the infant with single ventricle physiology.

Vamsi V Yarlagadda1, Melvin C Almodovar.   

Abstract

OPINION STATEMENT: Among patients with congenital heart defects, neonates with single ventricle disease continue to challenge clinicians despite significant improvements in survival over the past 30 years. The cardiac anatomical variants associated with the term "single ventricle" are characterized by severe hypoplasia (or absence) of either ventricle, typically in association with obstruction or atresia of either the pulmonary or systemic outflow tracts. Physiologically, the single ventricle receives both pulmonary and systemic venous blood and ejects simultaneously into the pulmonary and systemic circulations, a pattern commonly referred to as single ventricle physiology. Medical and surgical management strategies, though palliative, are aimed at achieving the optimal balance of systemic blood flow and pulmonary blood flow to maximize oxygen delivery. Patients with single ventricle physiology have a greater risk of dying than those with biventricular circulations and are generally committed to multiple palliative interventions throughout childhood with considerable risk. Surgical intervention in the newborn period involves Norwood Stage I palliation, placement of a systemic-to-pulmonary artery shunt, or banding of the pulmonary artery, depending on the status of the outflow tracts. Heart transplantation is offered as the initial approach in some centers. The management strategy and the actual delivery of care from the time of birth (or at time of diagnosis) through the postoperative period is crucial to optimize the short-term and long-term outcomes. Whereas survival following initial palliation in experienced centers is as high as 95%, emphasis is now appropriately shifting toward the control of in-hospital morbidity and optimizing long-term functional outcome. Centers are continually striving to gather and apply new knowledge related to the underlying anatomical and physiologic problems while seeking to improve decision making and care of the patient with single ventricle physiology.

Entities:  

Year:  2011        PMID: 21671164     DOI: 10.1007/s11936-011-0134-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  35 in total

1.  Effects of inspired hypoxic and hypercapnic gas mixtures on cerebral oxygen saturation in neonates with univentricular heart defects.

Authors:  Chandra Ramamoorthy; Sarah Tabbutt; C Dean Kurth; James M Steven; Lisa M Montenegro; Suzanne Durning; Gil Wernovsky; J William Gaynor; Thomas L Spray; Susan C Nicolson
Journal:  Anesthesiology       Date:  2002-02       Impact factor: 7.892

2.  Ring-enforced right ventricle-to-pulmonary artery conduit in Norwood stage I reduces proximal conduit stenosis.

Authors:  Christian Schreiber; Jelena Kasnar-Samprec; Jürgen Hörer; Andreas Eicken; Julie Cleuziou; Zsolt Prodan; Rüdiger Lange
Journal:  Ann Thorac Surg       Date:  2009-11       Impact factor: 4.330

3.  Perioperative monitoring in high-risk infants after stage 1 palliation of univentricular congenital heart disease.

Authors:  Nancy S Ghanayem; George M Hoffman; Kathleen A Mussatto; Michele A Frommelt; Joseph R Cava; Michael E Mitchell; James S Tweddell
Journal:  J Thorac Cardiovasc Surg       Date:  2010-10       Impact factor: 5.209

4.  Physiologic repair of aortic atresia-hypoplastic left heart syndrome.

Authors:  W I Norwood; P Lang; D D Hansen
Journal:  N Engl J Med       Date:  1983-01-06       Impact factor: 91.245

5.  Perinatal and early surgical outcome for the fetus with hypoplastic left heart syndrome: a 5-year single institutional experience.

Authors:  J Rychik; A Szwast; S Natarajan; M Quartermain; D D Donaghue; J Combs; J W Gaynor; P J Gruber; T L Spray; M Bebbington; M P Johnson
Journal:  Ultrasound Obstet Gynecol       Date:  2010-10       Impact factor: 7.299

6.  Right ventricle-pulmonary artery shunt in first-stage palliation of hypoplastic left heart syndrome.

Authors:  Shunji Sano; Kozo Ishino; Masaaki Kawada; Osami Honjo
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2004

7.  Hybrid approach for hypoplastic left heart syndrome: intermediate results after the learning curve.

Authors:  Mark Galantowicz; John P Cheatham; Alistair Phillips; Clifford L Cua; Timothy M Hoffman; Sharon L Hill; Roberta Rodeman
Journal:  Ann Thorac Surg       Date:  2008-06       Impact factor: 4.330

8.  Impact of mitral stenosis and aortic atresia on survival in hypoplastic left heart syndrome.

Authors:  Jenifer A Glatz; Raymond T Fedderly; Nancy S Ghanayem; James S Tweddell
Journal:  Ann Thorac Surg       Date:  2008-06       Impact factor: 4.330

9.  Early postoperative outcomes in a series of infants with hypoplastic left heart syndrome undergoing stage I palliation operation with either modified Blalock-Taussig shunt or right ventricle to pulmonary artery conduit.

Authors:  Clifford L Cua; Ravi R Thiagarajan; Kimberlee Gauvreau; Lillian Lai; John M Costello; David L Wessel; Pedro J Del Nido; John E Mayer; Jane W Newburger; Peter C Laussen
Journal:  Pediatr Crit Care Med       Date:  2006-05       Impact factor: 3.624

10.  Enteral feeding algorithm for infants with hypoplastic left heart syndrome poststage I palliation.

Authors:  Nancy J Braudis; Martha A Q Curley; Karen Beaupre; Kristi C Thomas; Gina Hardiman; Peter Laussen; Kimberlee Gauvreau; Ravi R Thiagarajan
Journal:  Pediatr Crit Care Med       Date:  2009-07       Impact factor: 3.624

View more
  1 in total

1.  Outcome of extremely preterm infants (<1,000 g) with congenital heart defects from the National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  Athina Pappas; Seetha Shankaran; Nellie I Hansen; Edward F Bell; Barbara J Stoll; Abbot R Laptook; Michele C Walsh; Abhik Das; Rebecca Bara; Ellen C Hale; Nancy S Newman; Nansi S Boghossian; Jeffrey C Murray; C Michael Cotten; Ira Adams-Chapman; Shannon Hamrick; Rosemary D Higgins
Journal:  Pediatr Cardiol       Date:  2012-05-30       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.